CHU Nantes - Hôtel Dieu

corporate_fareorganization

CHU Nantes - Hôtel Dieu

- Funding / Projects
  (52)

52 Projects, page 1 of 11

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant
assignment_turned_inProjectPartners:HUS, Groupe Hospitalier Pitié Salpétrière, HUG, Hôpital Claude Huriez, Centre Hospitalier Universitaire de Poitiers +10 partners
HUS,
Groupe Hospitalier Pitié Salpétrière,
HUG,
Hôpital Claude Huriez,
Centre Hospitalier Universitaire de Poitiers,
Centre Hospitalier Universitaire de Toulouse,
Centre Hospitalier Universitaire de Limoges,
Institut Paoli-Calmettes- (IPC),
CHRU MTP,
Hôpital Necker- Enfants malades,
HCL,
Institut de cancérologie Lucien Neuwirth,
CHU Nantes - Hôtel Dieu,
CHU,
Groupe Hospitalier Henri Mondor - Albert Chenevier
Funder: Institut National du Cancer Project Code: INCa-DGOS-11089
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Optimisation pharmacocinétique et par imagerie de l’immuno-TEP préciblée avec l’anticorps bispécifique anti-ACE x anti-HSG TF2 et le peptide IMP-288 marqué au Gallium-68 pour l’imagerie des patients atteints de récidives de carcinome médullaire de la thyroïde. Pharmacokinetic and imaging optimization study of pretargeted immuno-PET using the anti-CEA x anti-HSG TF2 bispecific antibody and 68Ga-IMP-288 peptide in patients with recurrences of medullary thyroid carcinoma.
assignment_turned_inProject2010 - 2013Partners:CHU, CHU Nantes - Hôtel Dieu, Centre Hospitalier Universitaire d'Angers, ORGANISME NON ASSOCIE, Institut de Cancérologie de l'Ouest +3 partners
CHU,
CHU Nantes - Hôtel Dieu,
Centre Hospitalier Universitaire d'Angers,
ORGANISME NON ASSOCIE,
Institut de Cancérologie de l'Ouest,
HCL,
INSERM UMR892,
Centre René Gauducheau
Funder: Institut National du Cancer Project Code: INCa-2664
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
CLIP²-ILIAD Imaging and Longitudinal Investigations to Ameliorate Decision making in oncology
assignment_turned_inProjectUntil 2024Partners:Centre Hospitalier Universitaire d'Angers, Centre René Gauducheau, Institut de Cancérologie de l'Ouest - ICO, CHU, CHU Nantes - Hôtel Dieu
Centre Hospitalier Universitaire d'Angers,
Centre René Gauducheau,
Institut de Cancérologie de l'Ouest - ICO,
CHU,
CHU Nantes - Hôtel Dieu
Funder: Institut National du Cancer Project Code: INCa-13732
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Evaluation of the 18-FDG PET scan for the diagnosis of degeneration of the intraductal papillary mucinous tumors of the pancreas (IPMT).
assignment_turned_inProjectPartners:CHU Nantes - Hôtel Dieu
CHU Nantes - Hôtel Dieu
Funder: Institut National du Cancer Project Code: INCa-DGOS-2572
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
Anti-infectious agent specificity of benign (MGUS) and malignant (myeloma) monoclonal gammopathies: a proof-of-principle study.
assignment_turned_inProject2010 - 2012Partners:CHU, ORGANISME NON ASSOCIE, CHU Nantes - Hôtel Dieu, Institut de Biologie de Nantes, Hôpital Femme-Enfant-Adolescent
CHU,
ORGANISME NON ASSOCIE,
CHU Nantes - Hôtel Dieu,
Institut de Biologie de Nantes,
Hôpital Femme-Enfant-Adolescent
Funder: Institut National du Cancer Project Code: INCa-2641
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu
more_vert
linkLink to
shareshareShare
uploaduploadDeposit
codecodeEmbed
Select content type to embed
All Research products
arrow_drop_down
COPY SCRIPT
For further information contact us at helpdesk@openaire.eu

chevron_left
1
2
3
4
5
chevron_right

CHU Nantes - Hôtel Dieu

CHU Nantes - Hôtel Dieu

52 Projects, page 1 of 11

ALTER-GREF: Randomized prospective phase II clinical trial using post-transplantation cyclophosphamide for prevention of GVHD in haploidentical and HLA 9/10 mismatched unrelated donors hematopoietic stem cell transplant

CLIP²-ILIAD Imaging and Longitudinal Investigations to Ameliorate Decision making in oncology

Evaluation of the 18-FDG PET scan for the diagnosis of degeneration of the intraductal papillary mucinous tumors of the pancreas (IPMT).

Anti-infectious agent specificity of benign (MGUS) and malignant (myeloma) monoclonal gammopathies: a proof-of-principle study.

Loading